Research Progress on a SARS-CoV-2 Vaccine in China
Research Progress on a SARS-CoV-2 Vaccine in China作者机构:Department of the Intensive Care Unit First Hospital of Jilin University Changchun China Department of Pathogen Biology College of Basic Medical Sciences Jilin University Changchun China Department of Respiratory and Critical Care Medicine First Hospital of Jilin University Changchun China Department of Hematology and Oncology Third Hospital of Jilin University Changchun China
出 版 物:《Journal of Biosciences and Medicines》 (生物科学与医学(英文))
年 卷 期:2021年第9卷第11期
页 面:76-88页
学科分类:1007[医学-药学(可授医学、理学学位)] 100705[医学-微生物与生化药学] 1001[医学-基础医学(可授医学、理学学位)] 100103[医学-病原生物学] 10[医学]
主 题:SARS-CoV-2 Whole-Virus Vaccines Adenovirus-Subunit Vaccines Recombinant Protein Vaccines
摘 要: Although many countries have controlled the pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) through strict management, there are still many countries with record-breaking numbers of new cases. Therefore, it is very important to develop a vaccine that can cause wide cross reactivity in clinical trials. At present, more than 90 vaccines are entering clinical trials and progressing smoothly, including inactivated vaccines, adenovirus-vectored vaccines and other types of vaccines. Here, we review and summarize the efficacy and potential threats of a SARS-CoV-2 vaccine. We reviewed whole-virus vaccines, adenovirus-subunit vaccines and recombinant protein vaccines and discussed the positive and negative consequences of a SARS-CoV-2 vaccine. However, there are still heated debates on the mechanism, effectiveness, and breadth of protection. In conclusion, this study can predict the risk of new coronavirus outbreaks in the future by discussing the research and development status of new coronavirus vaccines in China and other countries. Looking to the future, it is important to mine the large amount of data generated in clinical trials of universal new coronavirus vaccines to ensure that these vaccine programs are equally useful in the face of new coronavirus mutations.